

ADOCIA PROFILE OF BOARD MEMBERS PROPOSED TO THE ANNUAL SHAREHOLDER'S MEETING

Stéphane Boissel



Stéphane Boissel is currently Chairman and CEO of SpringVision, a genomic medicine company in ophthalmology.

He was previously Executive Vice President of Corporate Strategy at Sangamo Therapeutics, based in San Francisco (USA). He joined Sangamo Therapeutics on the back of the acquisition by the latter of TxCell SA, a CAR-Treg company he was the CEO of.

Stéphane is a seasoned biotech professional with over 25 years of leadership experience across corporate finance, strategy and business development.

Mr. Boissel completed his undergraduate work in management and finance at the University of Lyon and Paris-Dauphine in France and received his MBA from the University of Chicago (IL, USA).

Claudia Mitchell



Claudia Mitchell is the Senior VP, Head of Portfolio Strategy, at Astellas Pharma.

Claudia was the CEO and co-founder of Universal Cells, a Seattle-based biotech company, until the company was acquired by Astellas.

Claudia has previously co-founded Halo-Bio RNAi Therapeutics and served as its Chief Scientific Officer. She received the EY Entrepreneur of the Year award in Life Sciences for the Pacific NW Region in 2018.

Besides being a biotech entrepreneur, Claudia has also held positions in the non-profit sector and in Academia. She worked as the Program Director at the LGMD2I Research Fund, a family non-profit foundation, and has held a tenured Academic research position at the French National Institute of Medical Research (INSERM).

Claudia has a PhD in Molecular Biology from the University of Paris and an MBA in International Management from the Ecole des Ponts Business School, Paris, France.

Katherine Bowdish



Katherine Bowdish is the President & CEO of PIC Therapeutics, a venture-backed precision-medicine company focused in oncology.

From 2013 to 2020, Kathy worked for Sanofi to establish and lead Sanofi Sunrise, a venture investment/company co-creation and partnering vehicle focused on advancing pioneering science of strategic interest to Sanofi. Following a 5-year span leading Sunrise, Kathy accepted the role of Vice President and Head of R&D Strategy.

Prior to Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Past positions include Co-founder, President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.

Kathy holds a Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons in the City of New York, and a B.S. degree in biology from the College of William and Mary.